What changed for Multiple Sclerosis
A plain English summary of what recently moved in the public data Voxsanity tracks for Multiple Sclerosis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 337 to 341 (+4)
- Trials on record 2,926 to 2,955 (+29)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Multiple Sclerosis in July 2026. Voxsanity tracks 15 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 182 trials tracked for Multiple Sclerosis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05123703 · results posted 15 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05123703) enrolled 93 people in the ocrelizumab group and 94 people in the fingolimod group — 187 participants in total — all of whom had multiple sclerosis (MS). The trial compared these two medicines and measured things like how often participants experienced MS relapses (periods when symptoms flare up or get worse), changes seen on brain scans, and how ocrelizumab moved through the body. Notably, the data shows that zero participants in either group were recorded as having "completed" the study, with all participants li...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04815967 · results posted 27 May 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called MYOBLOC (a type of botulinum toxin) in people with muscle stiffness (a condition called spasticity). The trial had two phases: a blinded phase where 32 people were randomly assigned to receive either a high dose of MYOBLOC (10 people), a low dose of MYOBLOC (11 people), or a dummy treatment called a placebo (11 people), without knowing which they received. A further 24 people then entered an open-label extension phase, where everyone received MYOBLOC and knew they were doing so. The trial measured two m...
-
NCT04035005 · results posted 23 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04035005) enrolled around 505–508 people in the ocrelizumab group and 508 in the placebo group during the main double-blind phase. The trial was looking at a condition involving progressive disability — most likely primary progressive multiple sclerosis — and was primarily measuring how long it took before participants showed a meaningful, confirmed worsening in their disability. This worsening was tracked using two tools: a standard neurological scoring scale (where higher scores mean more disability) and a timed hand-and...
-
NCT04544436 · results posted 17 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04544436) enrolled 860 people with multiple sclerosis across two groups: 283 people received ocrelizumab at a dose of 600 mg, and 577 people received ocrelizumab at a higher dose of either 1,200 mg or 1,800 mg. The trial was designed to measure changes in disability over time, using three different tests — a standard neurological disability rating scale (called the EDSS), a timed 25-foot walking test, and a timed peg-placement hand test. The main question the trial was asking was how long it took before participants showed...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03594487 · results posted 3 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03594487) enrolled a total of five participants — four in the group who received a faecal microbiota transplant (FMT, a procedure where gut bacteria from a donor are transferred to a recipient) and one in an observational comparison group who did not receive the treatment. All five participants completed the study. The trial was primarily measuring whether participants could complete the full schedule of study visits (at the start, then at 2, 4, 8, and 12 weeks, plus a longer-term safety check-in up to week 48), how the va...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05888727 · results posted 30 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05888727) enrolled 23 people across two groups — 12 in an exercise training group and 11 in a wellness control group — though the recruitment goal recorded was 24 eligible participants overall. The study ran for 16 weeks and was primarily designed to test whether the trial itself was practical to run — in other words, could researchers recruit enough people, keep them involved throughout, and track any study-related unwanted events? These are known as "feasibility" measures, meaning the trial was checking whether a larger...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04230174 · results posted 30 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 people with multiple sclerosis, of whom 15 completed the study and 5 did not finish. The trial was measuring changes in brain scans over one year in people receiving a medicine called ocrelizumab. Researchers used specialised imaging to look at brain inflammation (using a type of scan called 11C-PBR28), the health of brain tissue (using a measure called magnetisation transfer ratio, or MTR — essentially a way of measuring how well the brain's structural proteins are holding together), the thickness of the brain's o...
-
NCT04353492 · results posted 12 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 562 people, all of whom received a treatment called ofatumumab. The trial was set up to measure how often participants experienced relapses (periods when multiple sclerosis symptoms flare up or worsen) over the course of the study. Specifically, it tracked the annualised relapse rate — that is, the average number of confirmed relapses per person per year. A total of 523 people completed the study, while 39 did not finish. The reported data shows that the average number of confirmed relapses per person per year was 0....
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05604170 · results posted 1 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05604170) enrolled 117 participants who were given ganaxolone oral suspension, taken three times a day. The trial was measuring a range of safety-related observations, including unwanted medical events (called adverse events), changes in vital signs such as heart rate and blood pressure, physical and neurological check-ups, developmental assessments in children, and heart rhythm readings (ECGs). The reported data shows that, when it came to unwanted medical events, 79 out of 117 participants experienced at least one treat...
-
NCT04667949 · results posted 29 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04667949) looked at fingolimod, a tablet used for multiple sclerosis (MS), in two groups of people in Australia: 11 participants who were under 18 years old, and 87 who were 18 or older. The main thing being measured was how often participants had MS relapses — that is, episodes where MS symptoms appeared or got noticeably worse. The trial also looked at changes seen on MRI brain scans and recorded any unwanted medical events (called adverse events) that occurred while people were taking the medication. The reported data...
-
NCT05323734 · results posted 11 July 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called ganaxolone in people with a rare genetic epilepsy condition called CDKL5 deficiency disorder (CDD), which causes frequent and difficult-to-control seizures. A total of 129 participants took part — 64 received ganaxolone and 65 received a placebo (a dummy treatment with no active ingredient). The main thing the trial was measuring was whether ganaxolone changed how often certain types of seizures occurred over a 28-day period compared to the start of the trial. The reported data shows that, on avera...
-
NCT04934800 · results posted 24 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 256 people with multiple sclerosis (MS) who were treated with a medicine called cladribine. A total of 234 people completed the study, while 22 did not finish. The trial was measuring changes in how often participants experienced MS relapses (episodes where symptoms appear or worsen) over two years, as well as any changes in their level of disability. The reported data shows that the main thing being measured — the average number of relapses per year — went down by 1.12 relapses per year when comparing the 12 months...
-
NCT01450072 · results posted 18 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01450072) involved 20 people with multiple sclerosis (MS) who had also been diagnosed with a condition called CCSVI — a proposed narrowing of veins that drain blood from the brain. Participants were split into two groups of 10: one group received a real balloon angioplasty procedure (a technique used to widen narrowed veins), while the other group received a sham (pretend) procedure involving only an imaging scan of the veins, with no actual treatment. The trial was measuring, firstly, how many people experienced serious u...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04411641 · results posted 18 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04411641) looked at a medicine called tolebrutinib (60 mg) compared to a placebo (an inactive dummy treatment) in people with multiple sclerosis (MS). In the main, double-blind phase of the trial — where neither participants nor their doctors knew who was getting which treatment — 377 people received the placebo and 754 received tolebrutinib. A smaller, open-label follow-on phase (where everyone knew they were receiving tolebrutinib) involved a further 196 participants. The trial's main focus was on measuring how long it t...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04338022 · results posted 12 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04338022) compared two treatments for multiple sclerosis (MS) — teriflunomide and evobrutinib — over a main treatment period of 156 weeks (about three years), followed by an extension period of a further 96 weeks (roughly two more years). A total of 564 people were assigned to the teriflunomide group and 560 to the evobrutinib group at the start of the main period. The trial's main focus was on measuring how often participants experienced MS relapses (episodes of new or worsening symptoms lasting more than 24 hours), and i...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05116540 · results posted 7 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05116540) looked at quality of life in people with multiple sclerosis (MS). A total of 24 people took part — 12 in the treatment group and 12 in the placebo group (a placebo is a dummy treatment with no active ingredient, used for comparison). Of those, 11 people in the treatment group and 10 in the placebo group completed the study. The trial measured quality of life using a 54-question MS-specific survey called the MSQOL-54, which covers areas like physical health, mental health, emotional wellbeing, cognitive function (...
-
NCT06019611 · results posted 27 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06019611) involved just 2 participants, both of whom completed the study. The trial was testing a technique called percutaneous epidural stimulation — where electrical signals are delivered to the spinal cord through the skin — in people with movement difficulties. The study measured a range of things including knee movement during walking, balance, muscle activity, muscle stiffness (called spasticity), and walking speed. Measurements were taken at the start of the study, at the end of the study with the stimulation turned...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04942938 · results posted 18 April 2025
According to the results reported on ClinicalTrials.gov, this trial involved 7 people with multiple sclerosis (MS), and all 7 completed the study — none dropped out. The trial was looking at a treatment called "Neubie" (a type of electrical stimulation device) and measured three things: a standard disability score used in MS called the Expanded Disability Status Scale (EDSS, where higher numbers mean greater disability), a 12-question self-reported walking scale (where a lower change score suggests less walking difficulty), and a muscle strength test across different muscle groups in the body....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05131971 · results posted 26 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 54 people in total. Fifteen participants received a placebo (an inactive treatment used for comparison), while the remaining 39 received one of seven different dose levels of the investigational medicine GSK3888130B — some given through a drip into the vein (IV) and some by injection under the skin (SC). All 54 participants who started the trial completed it. The trial was primarily focused on monitoring and counting any medical events or changes in blood and urine test results that occurred during the study period....
-
NCT04261790 · results posted 17 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 people with multiple sclerosis (MS), and all 10 completed the study — none dropped out. The trial was looking at what happens in the immune system before and after participants received a medicine called ocrelizumab. Specifically, researchers wanted to track changes in certain immune cells (called B-cells and T-cells) and the chemical signals they produce, to better understand how the treatment interacts with the immune system. The reported data shows that for all five of the trial's primary (main) outcome measure...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03853746 · results posted 5 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 people, all of whom received a treatment called ocrelizumab. Nine participants completed the study, and one did not. The trial was looking at whether signs of multiple sclerosis (MS) activity returned after the third month following the first infusion. This was checked either by finding new or growing areas of concern on MRI brain scans, or by a clinical relapse — meaning a return of MS symptoms confirmed by a neurological examination. The reported data shows that, out of the 10 participants, 3 showed a return of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03046251 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial followed 30 people with multiple sclerosis (MS) in the period after giving birth — 4 in the natalizumab group and 26 in a control group who were on other MS treatments. All 30 participants completed the study. The trial was measuring how often relapses (flare-ups of MS symptoms) occurred in the year after delivery, and also tracked changes in disability levels, brain scan findings, and quality of life over roughly 52 weeks. The reported data shows that, for the main thing being measured — relapses in the year after birth — 2...
-
NCT05028634 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial involved 63 participants in total — 30 in the ozanimod group and 33 in the comparison group (people not taking ozanimod). Ozanimod is a medicine used for certain conditions, and the trial was looking at how well participants' immune systems responded to two vaccines — a tetanus booster and a pneumococcal (pneumonia-related) vaccine — while on or off this medicine. All but one participant completed the study. The reported data shows some differences between the two groups in how their bodies responded to the tetanus booster va...
-
NCT04783935 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04783935) enrolled 219 adults with multiple sclerosis (MS) who were all treated with a medicine called cladribine. Of those, 206 people completed the study and 13 did not. The trial was an extension study — meaning participants had already been in an earlier ("parent") trial — and it followed them through years 3 and 4 of their overall treatment journey. The main thing researchers were tracking was called "NEDA-3," or "No Evidence of Disease Activity" across three measures: no relapses (flare-ups), no worsening of disabili...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03085810 · results posted 15 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03085810) involved a single treatment group receiving ocrelizumab, a medicine used in multiple sclerosis. A total of 1,225 people began the main part of the study, of whom 1,010 completed it. A separate sub-study ran alongside the main study, looking at two different ways of giving the infusion (a conventional infusion and a shorter infusion), with 373 people in each of those two groups. The trial was mainly tracking changes in participants' disability levels over time, using a standard scale called the EDSS (which runs fr...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04574024 · results posted 17 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04574024) involved people with multiple sclerosis (MS) who were given a treatment called NBT-NM108. Seven participants were enrolled at the start of the study. Of those, three went on to take NBT-NM108 for eight weeks, and two continued for twelve weeks. The trial was measuring three things in the blood and stool: levels of a protein called TNF-alpha (which is linked to inflammation in MS), the abundance of a type of gut bacteria called *Anaerostipes* (which tends to be lower in people with MS), and levels of a stool marke...
-
NCT04486716 · results posted 1 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04486716) enrolled 111 participants, all of whom received a treatment called ofatumumab at a dose of 20 mg. Of those, 102 were included in the main analysis, and 89 completed the core phase of the study. The trial was primarily looking at whether brain scans showed no increase — or a reduction — in a type of inflammation marker called gadolinium-enhancing lesions (bright spots visible on a specialised MRI scan that can indicate active inflammation in the brain) after 12 months of treatment. The reported data shows that, u...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05422625 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05422625) was designed to compare two versions of a nerve stimulation treatment — an active version (called PTNS, or percutaneous tibial nerve stimulation) and a sham (inactive/pretend) version — for bladder overactivity symptoms in people with multiple sclerosis (MS). The trial aimed to enrol participants in both groups, but the reported data shows that only 2 people were enrolled in the active treatment group and none in the sham group. Of those 2, only 1 person completed the trial. No results were reported for the sham...
-
NCT04754542 · results posted 25 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04754542) was an extension study that followed on from an earlier trial. A total of 76 people took part — 31 in a group that continued their disease-modifying medication and 45 in a group that stopped (discontinued) their medication. The trial was mainly measuring how many participants in each group showed signs of new inflammatory disease activity — meaning either a clinical relapse (a flare of symptoms) or a new lesion detected on a brain or spinal cord scan (MRI). The reported data shows that, for the primary outcome,...
-
NCT03157830 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 43 people who had been taking a MS medication called natalizumab and then switched to a different MS medication called ocrelizumab (brand name OCREVUS). Forty-one of the 43 participants completed the study. The trial was measuring how many participants remained free of MS relapses (episodes of worsening symptoms) over 12 months after switching, as well as tracking brain scan changes and a disability score over that same period. The reported data shows that at the 12-month mark, 95.2% of participants had not experienc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 182 reported results for Multiple Sclerosis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, Multiple Sclerosis currently attracts a very large amount of public research funding from the United States, and that investment has been rising year on year. This is an encouraging signal for patients, as sustained and growing public funding tends to support ongoing scientific inquiry, researcher training and the development of new treatment approaches over time. It...
See the full Multiple Sclerosis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.